Synerkine Pharma

Synerkine Pharma is an early-stage biotech developing a proprietary platform of cytokine fusion proteins, termed Synerkines, designed to treat conditions with high unmet medical need, particularly chronic pain. Its lead asset, SK-01, has received European Orphan Drug Designation for Complex Regional Pain Syndrome (CRPS), and a second program, SK-02, targets Chemotherapy-Induced Peripheral Neuropathy (CIPN). The company is backed by experienced life science investors like Flerie Invest and Thuja Capital and operates with a lean, experienced management team.

Proprietary platform for engineering fusion proteins called Synerkines, which connect two distinct cytokines into a single molecule to create a synergistic immunoregulatory effect.

Synerkine operates in the competitive neuropathic pain and immunomodulation space, competing with other biotechs developing biologics, antibodies, and small molecules targeting cytokines, nerve growth factors, and novel pathways. Its unique cytokine fusion approach is differentiated, but it will face competition from companies with more advanced clinical assets and greater resources.